Inebilizumab treatment in Japanese patients with IgG4-related disease: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE)

Modern Rheumatology · Published 2026-03-03 · DOI 10.1093/mr/roag020

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1093/mr/roag020

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Related articles